Vical entered into a co-development agreement for its Phase II anticancer therapy Allovectin-7® with Japanese biopharmaceutical company AnGes. As per the agreement AnGes will fund the Allovectin-7® Phase III trial and pay sales-based milestones and royalties for named Asian countries – where it has received exclusive rights from Vical. Vical retains the rights to Allovectin-7 in rest of the world.